ArticleActa pharmaceutica Sinica. B2026

APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma.

Linling Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.